Q3 2026 LeMaitre Vascular, Inc. Earnings Conference Call - LEMAITRE VASCULAR INC

Financial Performance:

• Q3 2026 organic revenue growth of 12% (7% price, 5% units); reported growth 11%, negatively impacted by $440k FX headwinds.
• Gross margin reached 71.7% (up 90 bps YoY); excluding a $0.5M inventory reserve for discontinued product FASTIP, adjusted gross margin was 72.4% (up 160 bps).
• Operating margin came in at 26% with operating income of $17.7M; full-year 2026 guidance set at 27% operating margin.
• Net income was $15M with diluted EPS of $0.65; Q3 free cash flow was $19.7M.
• Cash and investments balance stood at $390M at end of September.

Guidance and Future Outlook:

• Full-year 2026 guidance reiterated: 11% organic sales growth, 11% reported sales growth ($275.8M), and 18% EPS growth ($2.80).
• Full-year 2026 gross margin guidance adjusted to 72.1% (170 bps improvement from adjusted 2025).
• Q4 guidance reduced slightly to 11% organic growth (down from 12% in August forecast), primarily due to foreign exchange strengthening of the USD against the Euro and sales pull-forward into Q3.
• Management declined to provide specific 2027 guidance, citing the B. Braun acquisition transition complexity, but noted historical CAGR of 11-12%.

Business Segments and Product Lines:

• Grafts grew 20% and shunts 14%; biologics outpaced the portfolio with Artograft up 18% and Restorative Allografts (RestoreFlow) up 34%.
• Acquired B. Braun vascular assets (polyester/silver-coated grafts, etc.) in October; 2025 sales of $9.4M, primarily in Europe (65% in Europe, 21% in Germany).
• RestoreFlow cardiac tissue grew 65% YoY in Q3, though volume growth was constrained by processing throughput at the Burlington facility.
• International Autograft sales reached $3M in Q3; approvals secured in Brazil and Saudi Arabia (60 total countries); long-leg bypass grafts expected for approval in US/EU in late 2026 with sales starting H2 2027.
• Commercial infrastructure expansion: Sales force grew 19% to 171 reps; new offices in Poland and Malaysia planned for 2027; 30,000 sq ft added in Burlington for manufacturing consolidation.

Market and Competitive Landscape:

• Geographic growth: EMEA +18% (20% organic), Americas +9%, APAC +5%.
• Positioning: Acquisition of B. Braun assets aims to make LeMay the #3 player in worldwide vascular share ex-Japan.
• Competitive moat: Management emphasizes "no-backorder" commitment and local sales presence to capture market share from B. Braun's legacy bundling and direct sales.
• Market dynamics: Biologic grafts face competition from synthetic options; management notes US market for long biologic leg bypasses is limited compared to Europe.

Risks and Challenges:

• Regulatory/Supply: FDA observations on New Jersey facility pending re-inspection (likely 2027); RestoreFlow production bottleneck at Burlington causing inventory buildup ($14M) relative to demand; potential "breakage" of 10-15% during B. Braun commercial transition.
• Transition Complexity: B. Braun acquisition involves a 18-24 month commercial transition where B. Braun continues direct supply, delaying LeMay revenue recognition until orders are fulfilled directly by LeMay.
• FX Exposure: Strengthening US dollar impacting reported revenue growth and operating leverage on fixed costs.
• One-time charges: $0.5M inventory reserve due to FASTIP product discontinuation.

Management Commentary and Tone:

• Tone was confident and growth-oriented, highlighting "underlying profitability" (27% ROIC) and successful international expansion.
• Leadership transition noted: Dave Roberts concluding his tenure as President after 30 years; CEO George LeMaitre taking interim lead on biz dev; Tarek Pachuca hired as new Global Head of Marketing.
• Management emphasized strategic acquisition playbook (niche products + global channel) and commitment to long-term organic growth despite near-term integration costs.

Analyst Questions and Answers:

• B. Braun Acquisition: Confirmed transaction has been in gestation for 9-12 months; products are relatively flat but expected to grow under LeMay's model; transition to in-house manufacturing expected by late year 2 or year 3.
• RestoreFlow Constraints: Acknowledged current inability to meet all demand due to QC/release bottlenecks, though sourcing is sufficient; 65% increase in grafts approved in Q3.
• Margin Guidance: Q4 and full-year margin compression attributed to inventory reserve, accelerated sales force hiring, FX impacts, and timing of RestoreFlow transfer costs moving to COGS.
• Market/Cuts: Minimal impact from US Medicaid/Medicare policy uncertainty; procedures are DRG-coded and economically attractive, limiting volume sensitivity to reimbursement changes.
• Product Strategy: Long Autografts primarily target European leg bypass market; US market favors shorter grafts for AV access; no plans to introduce B. Braun polyester grafts in US due to entrenched duopoly.

Other Key Points:

• LeMay will apply for PMDA approval in Japan in Q4 2026, targeting 2029-2030 approval.
• The B. Braun portfolio includes no US/Canada revenue initially, opening opportunities for LeMay to enter direct sales in 5-9 new European countries (e.g., Slovakia).
• LeMay acquired 30,000 sq ft of space in Burlington (occupancy July 2027) to consolidate manufacturing and integrate acquisition supply chains.
• Management is recruiting additional senior business development executives to support continued acquisitive strategy.
• Q3 was the first full quarter for Autograft comps, showing positive traction in international markets.